GlassScriptPhysician profile
Tyler Matthew Bates
NPI 1538573571
$1,646.81
in general payments reported to CMS, 2019-2025
24 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $47.21 · 2021: $218 · 2022: $124 · 2023: $35.33 · 2024: $461 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.67 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $174.34 | 2024-2025 | Breztri, Airsupra, Fasenra |
| Dexcom, INC. | $125.57 | 2021-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $120.96 | 2019 | |
| Pfizer INC. | $117.88 | 2024-2025 | |
| Exact Sciences Corporation | $115.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $81.58 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $68.13 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $64.60 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.33 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $60.21 | 2022-2025 | |
| Irhythm Technologies, INC. | $55.36 | 2024 | Zio Xt Patch, Zio Monitor |
| Abbott Laboratories | $47.91 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $40.34 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $35.65 | 2021-2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $28.74 | 2025 | Skyclarys |
| Misonix INC | $26.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.79 | 2025 | Eliquis |
| Corcept Therapeutics | $25.60 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $20.04 | 2021 | |
| Lilly USA, LLC | $18.94 | 2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $18.53 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $16.28 | 2021 | |
| Eisai INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.